Dr. Hoppe is a senior clinician and scientist in the Hematology/Oncology Division and one of the leaders of the Hemoglobinopathy Center. As medical director of the Hemoglobinopathy Reference Laboratory at UCSF BCHO, Dr. Hoppe has interests in public health research and is involved in several CDC-sponsored projects to build diagnostic laboratory capacity for universal newborn screening and improved surveillance of hemoglobin disorders internationally. Dr. Hoppe’s research interests have focused on clinical and translational studies in sickle cell disease (SCD). Her research career started by investigating genetic modifiers of stroke using samples from children enrolled in the multi-institutional Cooperative Study of Sickle Cell Disease (CSSCD) and the Stroke Prevention Trial for Sickle Cell Anemia (STOP).

She has applied novel genotyping assays to identify potential risk-conferring genes in SCD. She collaborated on several projects using high-density genotyping and genome sequencing to identify genetic determinants of disease severity and Hb F response to hydroxyurea. As part of the NHLBI REDS-III project, she is identifying molecular determinants of alloimmunization and response to transfusion. Dr. Hoppe is actively involved in both investigator-initiated and industry-sponsored clinical trials in SCD. These studies include a phase 1/2 trial investigating the potential clinical efficacy of simvastatin in SCD and a global phase 3 clinical trial evaluating the efficacy of the platelet inhibitor, prasugrel, in preventing vaso-occlusive pain events in children with sickle cell disease.

Representative Publications:

A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events

Real-time dose adjustment using point-of-care platelet reactivity testing in a double-blind study of prasugrel in children with sickle cell anaemia

Successful utilization of an electronic pain diary in a multinational phase 3 interventional study of pediatric sickle cell anemia

Prasugrel for Sickle Cell Vaso-Occlusive Events

Inflammatory mediators of endothelial injury in sickle cell disease

Design of the DOVE (Determining Effects of Platelet Inhibition on Vaso-Occlusive Events) trial: A global Phase 3 double-blind, randomized, placebo-controlled, multicenter study of the efficacy and safety of prasugrel in pediatric patients with sickle cell anemia utilizing a dose titration strategy

Share

Discuss in Social Wall

Twitter

Share to SCDteam

+myBinder